Phase 3 N=121 An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
Sarcoma
Primary: Progression - Free Survival (PFS) — 19.6; 8.3 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=117 Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Great Saphenous Vein Incompetence · Visible Varicosities
Primary: Absolute Change From Baseline in Independent Photography Review (IPR-V3 Score) — -0.80; -1.30; -1.11 score
Phase 3 N=36 Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support)Device
Intracranial Aneurysms
Primary: Probable Benefit Measures as Successful Aneurysm Treatment With the LVIS™ Device, as Measured by Aneurysm Angiographic Occlusion of ≥ 90% at 6 Months (± 4 Weeks) — 95…
Phase 3 N=50 Paracervical Block in First Trimester Surgical Abortions
Pain · Surgical Abortion
Primary: Level of Pain During Specific Time Intervals Throughout D&C Procedure. — 52.2; 51.7; 33.6; 32.7 mm — p=0.94
Phase 3 N=983 A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)
Contraception
Primary: Pearl Index, by Treatment Group — 1.92; 3.12 Pregnancies per 100 woman-years — p=0.531
Phase 3 N=372 Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
Diabetic Macular Edema
Primary: Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12 — 62.3; 64.1; 65.1; 68.25 Letters
Phase 3 N=10,251 Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Atherosclerosis · Cardiovascular Diseases · Hypercholesterolemia
Primary: First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in…
Phase 3 N=47 Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
Cancer · Lymphoma · Leukemia
Primary: Number of Participants With Severe Oral Mucositis (WHO Grade 3 and 4) — 9; 6; 4; 9 participants
Phase 3 N=188 Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Mucositis · Solid Tumors · Stomatitis
Primary: Number of Participants With Severe (Grade 3 or 4) Oral Mucositis — 62; 51; 29; 43 participants — p=0.0410
Phase 3 N=67 Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
Schizophrenia · Schizoaffective Disorder · Agitation
Primary: The Change of the Positive and Negative Symptom Scale Excited Component (PANSS-EC) Score From Baseline to 120 Minutes After First Injection — -10.2; -9.9 units on a…
Phase 3 N=224 SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy
Rheumatoid Arthritis
Primary: Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS28-CRP) Area Under the Curve (AUC) at Week 104 — 2761.4; 2666.0 score on a scale*week
Phase 3 N=141 Treating Violence-Prone Substance Use Disorder Patients
Substance-related Disorders · Violence
Primary: Addiction Severity Index Legal Composite — .038; .012 units on a scale
Phase 3 N=365 Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
Mild Cognitive Impairment · Alzheimer's Disease
Primary: Hazard Ratio (HR) by PET Scan Readers for Conversion to Probable Alzheimer's Disease Based on Visual Image Interpretation. — 3.418; 1.962; 2.561; 2.633 Ratio of visual…
Phase 3 N=239 Can Group Visits Improve Outcomes of Veterans With Diabetes
Diabetes · Hypertension
Primary: Hemoglobin A1c — 8.4; 8.7 percentage points — p=0.15
Phase 3 N=193 A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
Rheumatoid Arthritis
Primary: Change From Baseline in DAS28 Score at Week 24 — -2.12 scores on a scale